You have Guest access.
Log In
Miguel H. Bronchud, Mary Ann Foote, Giuseppe Giaccone, Olufunmilayo Olopade and Paul Workman
i-xix
Front matter
1-26
Selecting the Right Targets for Cancer Therapy
27-41
Clinical Importance of Prognostic Factors Moving from Scientifically Interesting to Clinically Useful
43-84
Genetic Markers in Sporadic Tumors
85-105
Genetic Markers in Breast Tumors with Hereditary Predisposition
107-116
Circulating Tumor Markers
117-134
Antibody-Based Proteomics Analysis of Tumor Cell Signaling Pathways
135-152
Gene Expression Arrays for Pathway Analysis in Cancer Research
153-188
Signaling Pathways in Cancer
189-206
Estrogen Receptor Pathways and Breast Cancer
207-237
Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics
239-256
Angiogenesis Switch Pathways
257-268
Apoptosis Pathways and New Anticancer Agents
269-279
Genomic Instability, DNA Repair Pathways and Cancer
281-291
Epigenomics and Cancer
293-306
Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well?
307-315
Aurora Kinases: A New Target for Anticancer Drug Development
317-365
Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways
367-382
Suicide Gene Therapy
383-390
Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs
391-398
A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?
399-418
Back matter
This page requires script.
Frequently asked questions General info on journals and books Send us your feedback Impressum Contact us
© Springer, Part of Springer Science+Business Media Privacy, Disclaimer, Terms & Conditions, and Copyright Info